Literature DB >> 21132272

Development of a drug resistance model for hepatoblastoma.

Carmen Eicher1, Alexander Dewerth, Bettina Kirchner, Steven W Warmann, Jörg Fuchs, Sorin Armeanu-Ebinger.   

Abstract

Multidrug resistance (MDR) is a major reason for poor treatment results in hepatoblastoma (HB). The objective of this study was to establish a drug resistance model for HB to analyse alternative treatment options in vitro. Both HB cell lines HUH6 and HepT1 were xenotransplanted in NMRI mice (nu/nu) and 2 cycles of cisplatin (CDDP) treatment were administered. Thereafter, xenotransplants were excised and viable tumour cells were re-cultured. 3D cultures of HUH6 and HepT1 cells were generated on a low binding culture surface. Cell viability in response to CDDP/DOXO (doxorubicin) and apoptosis was assessed by MTT-assay and caspase 3 activity, respectively. Efflux of doxorubicin was measured by flow cytometry. Cellular levels of ABC-transporters (MDR1, MRP1, cMOAT and BRCP) were determined by real time rt-PCR. Only HepT1 cells isolated from HB xenografts showed resistance to CDDP, but did not survive repeated passages. Culturing HUH6 and HepT1 cells as spheroids was successful and 3D cultures showed an IC50-drift to higher drug concentrations for CDDP and DOXO compared to 2D cultures. Treatment with CDDP and DOXO led to homogeneous apoptosis in spheroids. Increased doxorubicin efflux in HUH6 spheroids was not influenced by the P-glycoprotein inhibitor tariquidar. Expression levels of MDR1, MRP1, cMOAT and BRCP in 3D cultures were similar to those in 2D cultures and were higher in HepT1 than in HUH6 cells. In conclusion, a 3D cell culture model for multidrug resistance was established for hepatoblastoma. The underlying mechanism involves altered accessibility of the cells for drugs rather than up-regulation of ABC-transporters.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21132272     DOI: 10.3892/ijo.2010.860

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

1.  A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma.

Authors:  Junegoo Lee; Tilahun Jiffar; Michael E Kupferman
Journal:  PLoS One       Date:  2012-01-20       Impact factor: 3.240

2.  Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells.

Authors:  Justus Lieber; Verena Ellerkamp; Julia Wenz; Bettina Kirchner; Steven W Warmann; Jörg Fuchs; Sorin Armeanu-Ebinger
Journal:  Pediatr Surg Int       Date:  2012-02       Impact factor: 1.827

3.  In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma.

Authors:  Alexander Dewerth; Timo Wonner; Justus Lieber; Verena Ellerkamp; Steven W Warmann; Jörg Fuchs; Sorin Armeanu-Ebinger
Journal:  Pediatr Surg Int       Date:  2012-04-18       Impact factor: 1.827

4.  Association Between ABCB1 (MDR1) Gene Polymorphism and Unresponsiveness Combined Therapy in Chronic Hepatitis C virus.

Authors:  Meryem Timucin; Hakan Alagozlu; Semra Ozdemir; Ozturk Ozdemir
Journal:  Hepat Mon       Date:  2013-04-13       Impact factor: 0.660

5.  Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma.

Authors:  Sorin Armeanu-Ebinger; Julia Wenz; Guido Seitz; Ivo Leuschner; Rupert Handgretinger; Ulrike A Mau-Holzmann; Michael Bonin; Bence Sipos; Jörg Fuchs; Steven W Warmann
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

Review 6.  Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma.

Authors:  Anna Alisi; William C Cho; Franco Locatelli; Doriana Fruci
Journal:  Int J Mol Sci       Date:  2013-12-18       Impact factor: 5.923

Review 7.  Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers.

Authors:  Jose J G Marin; Maria J Monte; Rocio I R Macias; Marta R Romero; Elisa Herraez; Maitane Asensio; Sara Ortiz-Rivero; Candela Cives-Losada; Silvia Di Giacomo; Javier Gonzalez-Gallego; Jose L Mauriz; Thomas Efferth; Oscar Briz
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

8.  Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma.

Authors:  Sorin Armeanu-Ebinger; Alexander Hoh; Julia Wenz; Joerg Fuchs
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

9.  PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.

Authors:  Raoud Marayati; Laura L Stafman; Adele P Williams; Laura V Bownes; Colin H Quinn; Jamie M Aye; Jerry E Stewart; Karina J Yoon; Joshua C Anderson; Christopher D Willey; Elizabeth A Beierle
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.